Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Ariosa Diagnostics
SAO PAULO, Sept. 12, 2013 /PRNewswire/ -- Ariosa Diagnostics announced today that it has launched an important partnership with Fleury Medicina e Saude (Fleury Group) to offer the Harmony™ Prenatal Test to obstetric healthcare providers throughout Brazil, a country with an annual birth rate of 2.99 million. With over 3,000 clinical laboratories and hospitals throughout the country, the Fleury Group has selected the Harmony test as its non-invasive prenatal test of choice for risk analysis of conditions such as Down syndrome.
With technology backed by clinical studies and published in high-impact peer-reviewed medical journals such as Prenatal Diagnosis, Fetal Diagnosis and Therapy and the American Journal of Obstetrics and Gynecology, the Harmony test provides Brazilian clinicians with a reliable, customized prenatal test for identifying the risk of fetal chromosome conditions in pregnant women. The test also includes an option for X and Y chromosome analysis, which provides information on sex chromosome conditions (i.e. Monosomy X or Klinefelter's syndrome) and fetal sex.
The Harmony test can be ordered by doctors for any singleton or twin pregnancy, including all those conceived by IVF. With a simple blood draw, the Harmony test can be performed as early as 10 weeks of pregnancy and offers a greater than 99 percent accuracy rate for risk assessment of trisomy 21, which causes Down syndrome. The Harmony test is backed by the most clinical data, including evaluation of over 30,000 pregnant patients worldwide, making it the most validated cell-free DNA test available.
Mário Burlacchini, PhD and Coordinator of Fetal Maternal Service at Fleury, said, "Now, we can provide a test with high sensitivity and less risk that generates less anxiety for our pregnant patients. This is a new era in fetal maternal medicine, and Fleury is committed to providing the best for its patients."
Ken Song, M.D., CEO of Ariosa Diagnostics, said, "We are pleased to have partnered with Fleury to offer the Harmony test to pregnant women in Brazil. Together, we will bring the highest quality and most clinically validated prenatal test for the betterment of prenatal medicine."
About Ariosa Diagnostics
Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the HarmonyTM Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The HarmonyTM Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.
The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com. Follow us on Twitter @HarmonyPrenatal and on Facebook at Harmony Prenatal for Healthy Pregnancy.
About Fleury Medicina e Saude
Fleury Medicina e Saude is a national benchmark in diagnostic medicine and it offers over 3,000 different tests in 37 different medical specialties. The brand is also a precursor in the concept of integrated medical centers that offer a complete diagnostic solution, medical advice and differentiated services. Fleury has 22 patient service centers in Sao Paulo, the biggest and most important city in Brazil. According to the Brazilian Institute of Public Opinion and Statistics (IBOPE) 2012 Survey, 74% of the physicians in Sao Paulo acknowledge Fleury as the best and most trusted brand for diagnostic medicine.
Ariosa Diagnostics, Inc.
+1 (202) 316 4553
(5511) 3897-4133 / 99916-8091
Ariosa Diagnostics, Inc.
Sabah Oney, PhD
+1 (408) 229 5115
©2012 PR Newswire. All Rights Reserved.